Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05099874 · ClinicalTrials.gov registry record · NA
Feasibility and Efficacy of Attentional-Control Training in Sickle Cell Disease
A NA study of Sickle Cell Disease and Attention-deficit, sponsored by Children's National Research Institute.
- Recruiting
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT05099874 is a NA study of Sickle Cell Disease and Attention-deficit that is actively recruiting participants, run by Children's National Research Institute. The registered enrollment target is 20 participants, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05099874, a NA study of Sickle Cell Disease and Attention-deficit, is actively recruiting participants, sponsored by Children's National Research Institute.
- RECRUITING
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Children with sickle cell disease (SCD) exhibit significantly reduced cognitive functioning (often difficulties with attention) compared to peers and siblings without SCD. EndeavorRx (Akili Interactive Labs: Boston, MA) is an FDA-approved home-based, electronic attentional-control training program designed to treat attention problems in youth. Users access EndeavorRx on a tablet device for 25-30 minutes each day, 5 days per week, for 4 weeks. The program involves training in a game-like environment that repeatedly challenges attentional-control abilities and adapts to user performance, becoming more difficult over time as performance improves. This pilot study is examining the feasibility, acceptability, and preliminary efficacy of EndeavorRx in a sample of 20 children with SCD ages 8-16 who are being treated with chronic blood transfusion therapy.
Conditions Studied
Interventions
- DEVICE EndeavorRx
Study Locations (1)
District of Columbia
- Children's National Hospital - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2022-12-20 |
| Est. Completion | 2025-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05099874
The ClinicalTrials.gov registry entry for NCT05099874 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (93% lower). The listed sponsor is Children's National Research Institute, which has 92 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Sickle Cell Disease appearing as the primary indexed condition, and to 1 intervention - of which EndeavorRx is the first listed.
NCT05099874 reports 1 study location spanning 1 distinct geographic area - top geographies include District of Columbia.
Frequently Asked Questions
What is clinical trial NCT05099874 about?
NCT05099874 is a clinical study titled "Feasibility and Efficacy of Attentional-Control Training in Sickle Cell Disease". Children with sickle cell disease (SCD) exhibit significantly reduced cognitive functioning (often difficulties with attention) compared to peers and siblings without SCD. EndeavorRx (Akili Interactive Labs: Boston, MA) is an FDA-approved home-based, electronic attentional-control training program d...
What is the current status of trial NCT05099874?
This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2022-12-20. Estimated completion is 2025-12.
What conditions does trial NCT05099874 study?
This clinical trial studies the following conditions: Sickle Cell Disease, Attention-deficit, Cognitive Deficit in Attention.
What interventions are being tested in trial NCT05099874?
The interventions under investigation include: EndeavorRx (DEVICE).
Who is sponsoring clinical trial NCT05099874?
This trial is sponsored by Children's National Research Institute, which has 92 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05099874 being conducted?
This trial has 1 study location across District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Early Life Exposures Among Children With Sickle Cell Disease
RECRUITING · NA
-
Exercise in Child Health
RECRUITING · NA
-
Sickle Cell Children's Exercise Study (SuCCESs)
RECRUITING · NA
-
Cutaneous Hydration Assessment in SCD
RECRUITING · NA
-
MULTIsite Feasibility of MUSIc Therapy to Address Quality Of Life in Sickle Cell Disease
RECRUITING · NA
-
Peer Support for Adolescents and Emerging Adults With Sickle Cell Pain
RECRUITING · NA
Explore more on PlainTrial
Sickle Cell Disease
All registered trials for this condition
Attention-deficit
All registered trials for this condition
District of Columbia
All trials with a study site in District of Columbia
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.